Emerging pharmaceutical therapies in cardiopulmonary resuscitation and post-resuscitation syndrome

Resuscitation

Volumn 82, Issue 4, 2011, Pages 371-377

  Charalampopoulos, Athanasios F ^a   Nikolaou, Nikolaos I ^a  

^a IASO GENERAL HOSPITAL   (Greece)

Author keywords

Cardiac arrest; Cardiopulmonary resuscitation; Drugs; Post cardiac arrest syndrome

Indexed keywords

ADRENALIN; ATENOLOL; BMS 191095; CARIPORIDE; CORBADRINE; DIAZOXIDE; DOBUTAMINE; ERYTHROPOIETIN; ESMOLOL; HYDROCORTISONE; LEVOSIMENDAN; METHYLPREDNISOLONE; NEUROTENSIN; NICORANDIL; NORADRENALIN; PENTAZOCINE; PHENYLEPHRINE; PINACIDIL; PLACEBO; PRAZOSIN; PROPRANOLOL; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; VASOPRESSIN;

ASYSTOLE; BLOOD CLOT LYSIS; BLOOD CLOTTING DISORDER; BODY TEMPERATURE; BRAIN DAMAGE; BRAIN PERFUSION; CARDIOPLEGIA; CEREBROVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; CONVALESCENCE; CORONARY ARTERY BLOOD FLOW; CORTICOSTEROID THERAPY; DEFIBRILLATION; DOSE RESPONSE; HEART ARREST; HEART INFARCTION; HEART MUSCLE METABOLISM; HEART OUTPUT; HEART PERFORMANCE; HEART PROTECTION; HOSPITAL DISCHARGE; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; INDUCED HYPOTHERMIA; LUNG EMBOLISM; MEDLINE; MONOTHERAPY; MORTALITY; MYOCARDIAL DISEASE; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OXYGEN SATURATION; PATHOPHYSIOLOGY; PATIENT CARE; PERFUSION PRESSURE; PRIORITY JOURNAL; RESUSCITATION; RETURN OF SPONTANEOUS CIRCULATION; REVIEW; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL RATE; VASODILATATION; VOLKMANN CONTRACTURE;

CARDIOPULMONARY RESUSCITATION; CARDIOVASCULAR AGENTS; HEART ARREST; HUMANS; HYPOXIA, BRAIN; PROGNOSIS; SYNDROME; TREATMENT OUTCOME;

EID: 79952629300     PISSN: 03009572     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.resuscitation.2010.12.017     Document Type: Review

References (73)

1. European Resuscitation Council Guidelines for Resuscitation 2005. Section 4. Adult advanced life support. Resuscitation 2005, 67S1:S39-S86.
2. Olasveengen T.M., Sunde K., Brunborg C., Thowsen J., Steen P.A., Wilk L. Intravenous drug administration during out-of-hospital cardiac arrest. JAMA 2009, 302:2222-2229.
3. Callaham M., Madsen C.D., Barton C.W., Saunders C.E., Pointer J. A randomized clinical trial of high-dose epinephrine and norepinehrine vs standard-dose epinephrine in prehospital cardiac arrest. JAMA 1992, 268:2667-2672.
4. Silfvast T., Saarnivaara L., Kinnunen A., et al. Comparison of adrenaline and phenylephrine in out-of-hospital cardiopulmonary resuscitation. A double-blind study. Acta Anaesthesiol Scand 1985, 29:610-613.
5. Wenzel V., Lindner K.H., Krismer A.C., Miller E.A., Voelckel W.G., Lingnaou W. Repeated administration of vasopressin but not epinephrine maintains coronary perfusion pressure after early and late administration during prolonged cardiopulmonary resuscitation in pigs. Circulation 1999, 99:1379-1384.
6. Lindner K.H., Dirks B., Strohmenger H.U., Prengel A.W., Lindner I.M., Lurie K.G. Randomised comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet 1997, 349:535-537.
7. Stiell I.G., Hebert P.C., Wells G.A., et al. Vasopressin versus epinephrine for in-hospital cardiac arrest: a randomised controlled trial. Lancet 2001, 358:10-105.
8. Wenzel V., Krismer A.C., Arntz R., et al. A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N Engl J Med 2004, 350:105-113.
9. AHA Guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Management of cardiac arrest. Circulation 2005, 112:IV-58-IV-66.
10. Mukoyama T., Kinoshita K., Nagao K., Tanjoh K. Reduced effectiveness of vasopressin in repeated doses for patients undergoing prolonged cardiopulmonary resuscitation. Resuscitation 2009, 80:755-761.
11. Gueugniaud P.Y., David J.S., Chanzy E., et al. Vasopressin and epinephrine vs. epinephrine alone in cardiopulmonary resuscitation. N Engl J Med 2008, 359:21-30.
12. Miller J.B., Donnino W.M., Rogan M., Goyal N. Relative adrenal insufficiency in post-cardiac arrest shock is under-recognized. Resuscitation 2008, 76:221-225.
13. Ito T., Saitoh D., Takasu A., et al. Serum cortisol as a predictive marker of the outcome in patients resuscitated after cardiopulmonary arrest. Resuscitation 2004, 62:55-60.
14. de Jong M.F.C., Beishuizen A., de Jong M.J., et al. The pituitary-adrenal axis is activated more in non-survivors than in survivors of cardiac arrest, irrespective of therapeutic hypothermia. Resuscitation 2008, 78:281-288.
15. Adrie C., Adib-Conquy M., Laurent I., et al. Successful cardiopulmonary resuscitation after cariac arrest as a 'sepsis-like' syndrome. Circulation 2002, 106:562-568.
16. Tsai M., Huang C., Chang W., et al. The effect of hydrocortisone on the outcome of out-of-hospital cardiac arrest patients: a pilot study. Am J Emerg Med 2007, 25:318-325.
17. Mentzelopoulos S.D., Zakynthinos S.G., Tzoufi M., et al. Vasopressin, epinephrine, and corticosteroids for in-hospital cardiac arrest. Arch Intern Med 2009, 169:15-24.
18. Frank S.M., Higgins M.S., Fleisher L.A., Sitzmann J.V., Raff H., Breslow M.J. Adrenergic, respiratory and cardiovascular effects of core cooling in humans. Am J Physiol 1997, 272:R557-562.
19. Bourque D., Daoust R., Huard V., Charneux M. β-Blockers for the treatment of cardiac arrest from ventricular fibrillation. Resuscitation 2007, 75:434-444.
20. Chen Z.M., Pan H.C., Chen Y.P., et al. Early intravenous then oral metoprolol in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005, 366:1622-1632.
21. Killingsworth C.R., Wei C., Dell'Italia L.J., et al. Short-acting β-adrenergic antagonist esmolol given at reperfusion improves survival after prolonged ventricular fibrillation. Circulation 2004, 109:2469-2474.
22. Jingjun L., Yan Z., Weijie, Dongdong Z., Guosheng L., Mingwei B. Effect and mechanism of esmolol given during cardiopulmonary resuscitation in a porcine ventricular fibrillation model. Resuscitation 2009, 80:1052-1059.
23. Bassiakou E., Xanthos T., Koudouna E., et al. Atenolol in combination with epinephrine improves the initial outcome of cardiopulmonary resuscitation in a swine model of ventricular fibrillation. Am J Emerg Med 2008, 26:578-584.
24. Ishibashi Y., Duncker D.J., Bashe R.J. Endogenous nitric oxide masks alpha 2-adrenergic coronary vasoconstriction during exercise in the ischemic heart. Circ Res 1997, 80:196-207.
25. Huang L., Sun S., Fang X., Tang W., Weil M.H. Simultaneous blockade of alpha-1 and β- actions of epinephrine during cardiopulmonary resuscitation. Crit Care Med 2006, 34:S483-S485.
26. Huang L., Weil M.H., Sun S., Tang W., Fang X. Carvedilol mitigates adverse effects of epinephrine during cardiopulmonary resuscitation. J Cardiovasc Pharmacol Ther 2005, 10:113-120.
27. Sun S., Weil M.H., Tang W., Kamohara T., Klouche K. a-Methylnorepinephrine, a selective a2-adrenergic agonist for cardiac resuscitation. J Am Coll Cardiol 2001, 37:951-956.
28. Ditchey R.V., Slinker B.K. Phenylephrine plus propranolol improves the balance between myocardial oxygen supply and demand during experimental cardiopulmonary resuscitation. Am Heart J 1994, 127:324-330.
29. Skrifvars M.B., Pettila V., Rosenberg P.H., Castren M. A multiple logistic regression analysis of in-hospital factors related to survival at six months in patients resuscitated from out-of-hospital ventricular fibrillation. Resuscitation 2003, 59:319-328.
30. Gonzalez M.M., Berg R.A., Nadkarni V.M., et al. Left ventricular systolic function and outcome after in-hospital cardiac arrest. Circulation 2008, 117:1864-1872.
31. + exchangers of mammalian cells. J Biol Chem 1997, 272:22373-22376.
32. Gazmuri R., Ayoub I.M., Kolarova J. Myocardial protection during resuscitation form cardiac arrest. Curr Opin Crit Care 2003, 9:199-204.
33. MacLellan W.R., Schneider M.D. Death by design: programmed cell death in cardiovascular biology and disease. Circ Res 1997, 81:137-144.
34. Grossman W., Barry W.H. Diastolic pressure-volume relations in the diseased heart. Fed Proc 1980, 39:148-155.
35. Franz M.R. Current status of monophasic action potential recording: theories, measurements and interpretations. Cardiovasc Res 1999, 41:25-40.
36. + exchanger inhibition modifies dopamine neurotransmission during normal and metabolic stress conditions. J Neurochem 2008, 106:231-243.
37. Ayoub I.M., Kolarova J., Gazmuri R.J. Cariporide given during resuscitation promotes return of electrically stable and mechanically competent cardiac activity. Resuscitation 2010, 81:106-110.
38. 2+ accumulation and attenuates myocardial injury. J Appl Physiol 2007, 103:55-65.
39. Mentzer R.M., Bartels C., Bolli R., et al. Sodium-hydrogen exchange inhibition by cariporide to reduce events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. Ann Thorac Surg 2008, 85:1261-1270.
40. Boyce S.W., Bartels C., Bolli R., et al. Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial inhibition in high-risk CABG patients: results of the CABG surgery cohort of the GUARDIAN study. J Thorac Cardiovasc Surg 2003, 126:420-427.
41. Smith K.J., Bleyer A.J., Little W.C., Sane D.C. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003, 59:538-548.
42. Huang C., Hsu C., Chen H., et al. Erythropoietin improves the postresuscitation myocardial dysfunction and survival in the asphyxia-induced cardiac arrest model. Shock 2007, 28:53-58.
43. Singh D., Kolarova J., Wang S., Ayoub I.M., Gazmuri R.J. Myocardial protection by erythropoietin during resuscitation from ventricular fibrillation. Am J Ther 2007, 14:361-368.
44. Incagnoli P., Ramond A., Joyeux-Faure M., Pepin J.L., Levy P., Ribuot C. Erythropoietin improved initial resuscitation and increased survival after cardiac arrest in rats. Resuscitation 2009, 80:696-700.
45. Celik M., Gokmen N., Erbayraktar S., et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA 2002, 99:2258-2263.
46. Cariou A., Claessens Y., Pene F., et al. Early high-dose erythropoietin and hypothermia after out-of-hospital cardiac arrest: a matched control study. Resuscitation 2008, 76:397-404.
47. Grmec S., Strnad M., Kupnik D., Sinkovic A., Gazmuri R.J. Erythropoietin facilitates the return of spontaneous circulation and survival in victims of out-of-hospital cardiac arrest. Resuscitation 2009, 80:631-637.
48. Nolan J.P., Neumar R.W., Adrie C., et al. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication: a scientific statement from the International Liaison Committee on Resuscitation; the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; the Council on Stroke (Part 1). Int Emerg Nurs 2009, 17:203-225.
49. Vasquez A., Karl K.B., Hilwig R.W., Heidenreich J., Berg R.A., Ewy G.A. Optimal dosing of dobutamine for treating post-resuscitation left ventricular dysfunction. Resuscitation 2004, 61:199-207.
50. Huang L., Weil M.H., Sun S., Cammarata G., Cao L., Tang W. Levosimendan improves postresuscitation outcomes in a rat model of CPR. J Lab Clin Med 2005, 146:256-261.
51. Huang L., Weil M., Tang W., Sun S., Wang J. Comparison between dobutamine and levosimendan for management of postresuscitation myocardial dysfunction. Crit Care Med 2005, 33:487-491.
52. Koudouna E., Xanthos T., Bassiakou E., et al. Levosimendan improves the initial outcome of cardiopulmonary resuscitation in a swine model of cardiac arrest. Acta Anaesthesiol Scand 2007, 51:1123-1129.
53. Xanthos T., Bassiakou E., Koudouna E., et al. Combination pharmacotherapy in the treatment of experimental cardiac arrest. Am J Emerg Med 2009, 27:651-659.
54. Wang J., Weil M.H., Tang W., Sun S., Huang L. Levosimendan improves post-resuscitation myocardial dysfunction after beta-adrenergic blockade. J Lab Clin Med 2005, 146:179-183.
55. Sigg D.C., Coles J.A., Oeltgen P.R., Iaizzo P.A. Role of delta-opioid receptor agonists on infarct size reduction in swine. Am J Physiol Heart Circ Physiol 2002, 282:H1953-H1960.
56. Fang X., Tang W., Sun S., Weil M.H. δ-Opioid-induced pharmacologic myocardial hibernation during cardiopulmonary resuscitation. Crit Care Med 2006, 34:S486-S489.
57. Shan Y., Sun S., Yang X., Weil M.H., Tang W. Opioid receptor agonist reduces myocardial ischemic injury when administered during early phase of myocardial ischemia. Resuscitation 2010, 81:761-765.
58. Gao C.J., Li J.P., Wang W., et al. Effects of intracerebroventricular application of the delta opioid receptor agonist [d-Ala2, d-Leu5] enkephalin on neurological recovery following asphyxial cardiac arrest in rats. Neuroscience 2010, 168:531-542.
59. Fisher M., Bottiger B.W., Popov-Cenic S., Hossmann K.A. Thrombolysis using plasminogen activator and heparin reduces cerebral no-reflow after resuscitation from cardiac arrest: an experimental study in the cat. Intensive Care Med 1996, 22:1214-1223.
60. Böttiger B.W., Bode C., Kern S., et al. Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trial. Lancet 2001, 357:1583-1585.
61. Böttiger B., Arntz H., Chamberlain D., et al. Thrombolysis during resuscitation for out-of-hospital cardiac arrest. N Engl J Med 2008, 359:2651-2662.
62. Arntz H.R., Wenzel V., Dissmann R., Marschalk A., Breckwoldt J., Müller D. Out-of-hospital thrombolysis during cardiopulmonary resuscitation in patients with high likelihood of ST-elevation myocardial infarction. Resuscitation 2008, 76:180-184.
63. Er F., Nia A.M., Gassanov N., Caglayan E., Erdmann E., Hoppe U.C. Impact of rescue-thrombolysis during cardiopulmonary resuscitation in patients with pulmonary embolism. PLoS One 2009, 4:e8323.
64. Popp E., Schneider A., Vogel P., Teschendorf P., Bottiger B.W. Time course of the hypothermic response to continuously administered neurotensin. Neuropeptides 2007, 41:349-354.
65. Quindry J.C., Schreiber L., Hosick P., Wrieden J., Irwin J.M., Hoyt E. Mitochondrial KATP channel inhibition blunts arrhythmia protection in ischemic exercised hearts. Am J Physiol Heart Circ Physiol 2010, 299:H175-H183.
66. Olson T.M., Alekseev A.E., Moreau C., et al. KATP channel mutation confers risk for vein of Marshall adrenergic atrial fibrillation. Nat Clin Pract Cardiovasc Med 2007, 4:110-116.
67. Kane G.C., Liu X.K., Yamada S., Olson T.M., Terzic A. Cardiac KATP channels in health and disease. J Moll Cell Cardiol 2005, 38:937-943.
68. Busija D.W., Gaspar T., Domoki F., Katakam P.V., Bari F. Mitochondrial-mediated suppression of ROS production upon exposure of neurons to lethal stress: mitochondrial targeted preconditioning. Adv Drug Deliv Rev 2008, 60:1471-1477.
69. Marinovic J., Ljubkovic M., Stadnicka A., Bosnjak Z.J., Bienengraeber M. Role of sarcolemmal ATP-sensitive potassium channel in oxidative stress-induced apoptosis: mitochondrial connection. Am J Physiol Heart Circ Physiol 2008, 294:H1317-H1325.
70. Deja M.A., Malinowski M., Golba K.S., et al. Diazoxide protects myocardial mitochondria, metabolism and function during cardiac surgery: a double-blind ramdomized feasibility study of diazoxide-supplemented cardioplegia. Thorac Cardiovasc Surg 2009, 137:997-1004.
71. Stadlbauer K.H., Rheinberger K., Wenzel V., et al. The effects of nifedipine on ventricular fibrillation mean frequency in a porcine model of prolonged cardiopulmonary resuscitation. Anesth Anal 2003, 97:226-230.
72. Reis A.G., de Paiva E.F., Schvartsman C., Zaritsky A.L. Magnesium in cardiopulmonary resuscitation: critical review. Resuscitation 2008, 77:21-25.
73. Niemann J.T., Youngquist S., Rosborough J.P., Shah A.P., Phan Q.T., Filler S.G. Infliximab attenuates early myocardial dysfunction after resuscitation in a swine cardiac arrest model. Crit Care Med 2010, 38:1162-1167.